Opinion|Videos|September 23, 2024
Impact of Dose Modifications on CLL Treatment
The discussion explores the frequency and impact of dose modifications due to adverse events, strategies for maintaining outcomes, monitoring protocols, and how these modifications affect long-term CLL therapy effectiveness and treatment decisions.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How frequently do patients require dose modification due to adverse events?
- How does dose modification impact the patient’s outcomes, and what strategies are employed to maintain optimal outcomes?
- What monitoring protocols are implemented for patients after dose modification, and how do these protocols help in maintaining treatment efficacy and patient safety?
- How do dose modifications impact the long-term effectiveness of chronic lymphocytic leukemia therapies, and how does this information guide treatment decisions?
Advertisement
Related to this article
BRUIN CLL-313 showed significantly longer progression-free survival vs bendamustine plus rituximab, bringing a noncovalent BTK inhibitor to first-line care.
A behavioral walking program matched supervised aerobic training for improving asthma control in a randomized trial of physically inactive adults.
Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1c by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
American Pharmacists Month kicked off on October 1, honoring more than 700,000 pharmacy professionals and 250 years of caring for America's communities.
fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.
Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.
A pharmacist-led collaborative drug therapy management program at NYC Health + Hospitals/Bellevue reported high patient satisfaction, and every surveyed patient said they felt respected and supported by their pharmacist.
A Novo Nordisk–funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, although the findings cannot show causation.
Advertisement
Advertisement
Trending on Pharmacy Times
1
EloraTZP Delivers Up to 23.3% Weight Loss in Adults With Obesity and T2D
2
Pharmacists Key to Lp(a) Counseling and Lipid Optimization
3
Why Lp(a) Testing Lagged Behind LDL Cholesterol Screening
4
What the 2025-2030 Dietary Guidelines Mean for Heart Health
5